Drugs / CD19CAR/virus specific T cells
CD19CAR/virus specific T cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00840853 | Apr 2009 → Apr 2016 overdue | B-cell acute lymphoblastic leukemia, B-cell chronic lymphocytic leukemia | Baylor College of Medicine | Active not recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19CAR/virus specific T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00840853 ↗ |
| Known as | CD19 chimeric receptor trivirus specific T cells | “The donor gave us blood to make CD19 chimeric receptor trivirus specific T cells in the laboratory.” NCT00840853 ↗ |
| Known as | CD19-redirected virus-specific T cells | “Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study.” PMID 24030379 ↗ Sep 2013 |
| Known as | CD19.CAR-modified VSTs | “This theory was evaluated by Cruz et al. in a previous clinical trial with CD19.CAR-modified VSTs, but there was little apparent expansion of these cells in patients.” PMID 25734008 ↗ Feb 2015 |
| Known as | CD19.CAR-VSTs | “We treated 8 patients with allogeneic (donor-derived) CD19.CAR-VSTs 3 months to 13 years after HSCT.” PMID 24030379 ↗ Sep 2013 |
| Action | Deplete | “T cells (CTLs or cytotoxic T cells) are infection-fighting blood cells that can kill cells, including tumor cells.” NCT00840853 ↗ |
| Modality | Cell therapy | “These CD19 chimeric receptor trivirus specific T cells are an investigational product not approved by the FDA.” NCT00840853 ↗ |
| Route | Intravenous | “given by intravenous injection” NCT00840853 ↗ |